Ending Patent Dispute, Bio-Rad and QIAGEN Agree to Cross-Licensing Arrangement

Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) and QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard: QIA) have reached a settlement in their long-standing patent dispute in the U.S. District Court of Delaware.

Through the negotiation of a global settlement and patent cross-licensing agreement, the two incorporations have agreed to settle their dispute over digital PCR technology. The agreement, mutually beneficial to both companies, will allow them to co-exist peacefully in the marketplace and continue to expand and innovate within their respective fields.

Bio-Rad and QIAGEN have recently agreed to a cross-licensing deal, unlocking the potential of their respective digital PCR technologies. This mutual agreement grants both parties the opportunity to leverage each other’s capabilities and drive innovation within the field.

About Bio-Rad

Bio-Rad Laboratories, Inc. is an industry leader in life science research and clinical diagnostics with an expansive network of research, development, and manufacturing operations across the globe. Our comprehensive portfolio of products has enabled us to reach over 8,000 employees and $2.8 billion in revenues in 2022, as customers all over the world rely on us to provide them with innovative, top-grade solutions that make a real difference in their line of work.

Whether it’s universities, research institutions, hospitals, or biopharmaceutical companies, we are committed to continuing our mission to advance science and save lives.


QIAGEN – a Netherlands-based holding company – is a world-leader when it comes to Sample to Insight solutions. For over 500,000 customers in two industries, Molecular Diagnostics for human healthcare and Life Sciences for forensics, academia, pharma R&D and industrial applications, QIAGEN offers insights on a molecular level that can be life-changing. With a net sales of over $2.1 billion and a team of 6,200 employees in 2022, QIAGEN is transforming the world of innovation.

Leave a Comment